senile

(redirected from Senile osteoporosis)
Also found in: Dictionary, Thesaurus, Encyclopedia, Wikipedia.
Related to Senile osteoporosis: osteomalacia, Postmenopausal osteoporosis

senile

 [se´nīl]
pertaining to old age; see also aged. Called also gerontic.

se·nile

(sē'nīl, sen'īl), Negative or pejorative connotations of this word may render it offensive in some contexts.
Relating to or characteristic of old age.
[L. senilis]

senile

/se·nile/ (se´nīl) pertaining to old age; manifesting senility.

senile

(sē′nīl′, sĕn′īl′)
adj.
a. Relating to or having diminished cognitive function, as when memory is impaired, because of old age.
b. Being a disease or condition whose cause is primarily advanced age: senile cataracts.

se′nile′ly adv.
se·nil′i·ty (sĭ-nĭl′ĭ-tē) n.

senile

[sē′nīl]
Etymology: L, senilis, aged
pertaining to or characteristic of old age or the process of aging. See also aging. senility, n.

se·nile

(sen'il)
Relating to or characteristic of old age.
[L. senilis]

senile

Pertaining to old age. From the Latin senilis, old.

se·nile

(sen'il) Negative or pejorative connotations of this word may render it offensive in some contexts.
Relating to or characteristic of old age.
[L. senilis]

senile

pertaining to old age; manifesting senility.

senile deafness
due probably to degeneration of the hair cells in the organ of Corti, and to loss of neurons in the spinal ganglion; called also presbycusis.
senile osteoporosis
reduced mineralization of bone due to advanced age.
senile retinopathy
see senile retinopathy.
References in periodicals archive ?
continue to commercialize Hectorol Injection in the end stage renal disease marketplace, -- complete FDA post-approval Phase IV commitments for Hectorol Injection, -- seek FDA approval and commercialization of Hectorol Capsules in the pre-dialysis marketplace, -- develop additional clinical indications for Hectorol Capsules by conducting Phase II, and possibly Phase III, trials in patients with senile osteoporosis, psoriasis and prostate cancer, -- continue research and development of new D-hormone therapies and -- provide working capital for general corporate purposes.
Because postmenopausal osteoporosis in women and senile osteoporosis in both sexes are global epidemiological problems, biochemical markers of bone turnover have become important clinical tests.
The Company will use its net proceeds from the offering to: (1) commercialize Hectorol Injection to manage secondary hyperparathyroidism in patients with end-stage renal disease; (2) complete FDA post-approval Phase IV commitments for Hectorol Injection; (3) seek FDA approval and commercialize Hectorol Capsules in the pre-dialysis market; (4) develop additional clinical indications for Hectorol Capsules by conducting Phase II, and possibly Phase III, trials in patients with senile osteoporosis, psoriasis and prostate cancer; (5) continue research and development activities on new vitamin D hormone therapies; and (6) provide working capital for general corporate purposes.